List of nationally authorised medicinal products

Similar documents
List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

FIREARMS IN THE EU September respondents. EU Member States PUBLIC PERCEPTIONS OF FIREARMS

ROAD SAFETY: Towards a European Road Safety Area: Policy orientations on road safety

Information on the implementation of Commission Regulation (EC) No 504/2008 on the identification of equidae

Unprotected road users left behind in efforts to reduce road deaths 5 th PIN Conference 21 June Henk Stipdonk, SWOV

Life Domain: Education and Vocational Training Goal Dimension: Objective Living Conditions

Steve Laffey Railroad Safety Specialist Illinois Commerce Commission.

Iran and the future of European Gas Supply the European Perspective

MFF and the CAP Legislative financial statement

Organisation Management Services (OMS) operating model

Country

PIN Flash 18 - Background tables

1. Annex 1: Indicators

Time series of Staff PPPs

SEASONAL DISTRIBUTIONS OF ROAD FATALITIES IN EUROPE

ROAD SAFETY: the European Union Strategy and Efforts

Safety culture in professional road transport in Norway and Greece

Posting of workers in the European Union and EFTA countries : Report on A1 portable documents issued in 2010 and 2011

Traffic Safety Basic Facts Main Figures. Traffic Safety Basic Facts Junctions

Update of trade weights data underlying the EERs and HCIs

Heavy Goods Vehicles and Buses

MARIE SKŁODOWSKA-CURIE ACTIONS STATISTICS INDIVIDUAL FELLOWSHIPS

The Sustainability of Public Finances in Belgium: Regional, Federal and EU Perspectives

Future of Collective Bargaining in Germany and the Importance of the recently introduced Minimum Wage Regulations

Traffic Safety Basic Facts Main Figures. Traffic Safety Basic Facts Traffic Safety. Gender Basic Facts Gender

Traffic Safety Basic Facts 2008

Standard Eurobarometer 84 Autumn Report. Media use in the European Union

Report. ESMA Data on Prospectuses Approved and Passported - January 2012 to December June 2013 ESMA/2013/741

Beyond market forces: a story of changing economic inequalities in rich countries

Traffic Safety Basic Facts 2010

List of selected projects Creative Europe - Media. Development of audiovisual content - Slate Funding Application deadline: Feb 6, 2018

The European Research Council

Report. ESMA Data on Prospectuses Approved and Passported January 2013 to December October 2014 ESMA/2014/1276

Transport safety culture in private and professional road transport in Norway and Greece (the SafeCulture project)

Traffic Safety Basic Facts 2008

Traffic Safety Basic Facts 2012

EU-Labour Force Survey November 2015 release. Setup for Importing the Anonymised Yearly Data Sets for

Traffic Safety Basic Facts 2008

Exposure estimations before and after the new EFSA-Guidance ECPA s perspective based on examples

Traffic Safety Basic Facts Main Figures. Traffic Safety Basic Facts Cyclists

STATISTICS

Traffic Safety Basic Facts 2011

Traffic Safety Basic Facts Main Figures. Traffic Safety Basic Facts Cyclists

outside motorways in 17 European Union countries Figure 1: Fatalities on ROU areas in EU-17 2, ,4

Fatal Train accidents on Europe`s railways: Prof. Andrew Evans from CTS, Imperial College London. Wednesday, 02 March :00

Public Procurement Indicators 2014

Premium T-Shirt. Premium T-Shirt -KIDS. T-Shirt Lady Fashion. Price Public 29,00 Availability: 5 to 7 work days

Country fact sheet Germany

Traffic Safety Basic Facts 2012

Traffic Safety Basic Facts 2010

The European Research Council (ERC) is the first pan-european funding body supporting the best frontier research in Europe 1.

Traffic Safety Basic Facts 2011

Deliverable D3.2 Assembly of Basic Fact Sheets 2010

Education and Training 2020: progress being made?

Facts and figures on the CFP. Basic data on the Common Fisheries Policy

Traffic Safety Basic Facts Main Figures. Traffic Safety Basic Facts Traffic Safety. Main Figures Basic Facts 2015.

Installation and operation manual SUNWOOD MARINO LPG

Land management and hunting in Hungary

Public Procurement Indicators 2015

The European Research Council

Facts and figures on the CFP BASIC DATA ON THE COMMON FISHERIES POLICY

Public data underlying the figures of Annual Report on the Results of Monitoring the Internal Electricity and Natural Gas Markets in 2016

Road traffic accidents in European urban areas

Traffic Safety Basic Facts 2010

EP A1 (19) (11) EP A1. (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC

Traffic Safety Basic Facts 2012

TEPZZ _ Z684A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A01D 34/82 ( )

Traffic Safety Basic Facts 2012

Facts and figures on the CFP. Basic data on the Common Fisheries Policy

AUSTRIA CONNECT Bogota, October 9, 2017

fatalities has reduced by more than 35%. Table 1: Pedestrian fatalities by country by year,

Traffic Safety Basic Facts 2010

Gianfranco Pacchioni Università Milano Bicocca 12/3/2014

AGRICULTURE IN ICELAND A GRASSLAND BASED PRODUCTION ÁSLAUG HELGADÓTTIR, EMMA EYTHÓRSDÓTTIR AND TORFI JÓHANNESSON

CHANGEOVER OF THE QUARTERLY FINANCIAL ACCOUNTS IMPACT ASSESSMENT. Executive Summary TO ESA 2010 AND GUIDELINE ECB/2013/24:

Eurostatistics DATA FOR SHORT-TERM ECONOMIC ANALYSIS 04/2018. Statistical

Traffic Safety Basic Facts 2012

The UPOV Convention: an International Standard

TEPZZ 9_ 9 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2015/36

Summary Charts Scenario 1 - Base Scenario

Road Safety Country Overview November Norway

TEPZZ A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2013/48

CERN Personnel Statistics

TEPZZ A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION

BUILDING THE CZECH ROAD SAFETY OBSERVATORY

European Bathing Water Quality in 2017 ISSN /

Youngsters (Aged 15-17)

European Trend Chart on Innovation EUROPEAN INNOVATION SCOREBOARD 2005 COMPARATIVE ANALYSIS OF INNOVATION PERFORMANCE

The ERC s quest to support excellent researchers all over Europe

TEPZZ 69Z 85A T EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION

Road Safety Country Overview November Poland

Transcription:

13 September 2017 EMA/699929/2017 Human Medicines Evaluation Division Active substance(s): bendamustine hydrochloride Procedure No.: PSUSA/00003162/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact An agency of the European Union European Medicines Agency, 2017. Reproduction is provided the source is acknowledged.

Levact 100 mg Powder for DE/H/1250/01/DC PA 731/5/2 ASTELLAS PHARMA GMBH IE Concentrate for Solution for Infusion Levact 2,5 mg/ml DE/H/1250/01/DC 44/0439/11-S ASTELLAS PHARMA GMBH SK Levact 2,5 mg/ml DE/H/1250/01/DC 44/0439/11-S ASTELLAS PHARMA GMBH SK Levact 2,5 mg/ml pó para DE/H/1250/01/DC 5411277 ASTELLAS PHARMA GMBH PT concentrado para soluҫão para perfusão Levact 2,5 mg/ml polvere per DE/H/1250/01/DC 040175046/M ASTELLAS PHARMA GMBH IT Levact 2,5 mg/ml polvere per DE/H/1250/01/DC 040175010/M ASTELLAS PHARMA GMBH IT Levact 2,5 mg/ml polvere per DE/H/1250/01/DC 040175034/M ASTELLAS PHARMA GMBH IT Levact 2,5 mg/ml polvere per DE/H/1250/01/DC 040175022/M ASTELLAS PHARMA GMBH IT DE/H/1250/01/DC 5363-I-2143/11 ASTELLAS PHARMA GMBH SI EMA/699929/2017 Page 2/6

Levact 2,5 mg/ml pulver til konsentrat til infusjonsvæske, oppløsning DE/H/1250/001 5363-I-2140/11 ASTELLAS PHARMA GMBH SI DE/H/1250/001 5363-I-2142/11 ASTELLAS PHARMA GMBH SI DE/H/1250/001 5363-I-2142/11 ASTELLAS PHARMA GMBH SI DE/H/1250/01/DC 1-29469 ASTELLAS PHARMA GMBH AT DE/H/1250/01/DC 1-29469 ASTELLAS PHARMA GMBH AT DE/H/1250/001 70972.00.00 ASTELLAS PHARMA GMBH DE DE/H/1250/001 70972.00.00 ASTELLAS PHARMA GMBH DE DE/H/1250/001 BE376022 ASTELLAS PHARMA GMBH BE DE/H/1250/001 BE376013 ASTELLAS PHARMA GMBH BE DE/H/1250/001 BE376013 ASTELLAS PHARMA GMBH BE DE/H/1250/001 BE376022 ASTELLAS PHARMA GMBH BE DE/H/1250/01/DC 07-5258 ASTELLAS PHARMA GMBH NO EMA/699929/2017 Page 3/6

Levact 2,5 mg/ml pulver til konsentrat til infusjonsvæske, oppløsning Levact 2,5 mg/ml stofn fyrir innrennslisþykkni, lausn Levact 2,5 mg/ml stofn fyrir innrennslisþykkni, lausn Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión LEVACT 2,5 mg/ml, poudre pour LEVACT 2,5 mg/ml, poudre pour Levact 2,5 mg/ml, poudre pour Levact 2,5 mg/ml, poudre pour Levact 2,5 mg/ml, prášek pro přípravu koncentrátu pro přípravu infuzního roztoku DE/H/1250/01/DC 07-5258 ASTELLAS PHARMA GMBH NO DE/H/1250/01/DC IS/1/11/044/01 ASTELLAS PHARMA GMBH IS DE/H/1250/01/DC IS/1/11/044/01 ASTELLAS PHARMA GMBH IS DE/H/1250/001 BE376013 ASTELLAS PHARMA GMBH BE DE/H/1250/001 BE376022 ASTELLAS PHARMA GMBH BE DE/H/1250/001 RVG 109342 ASTELLAS PHARMA GMBH NL DE/H/1250/001 RVG 109342 ASTELLAS PHARMA GMBH NL DE/H/1250/01/DC 72571 ASTELLAS PHARMA GMBH ES DE/H/1250/01/DC 72571 ASTELLAS PHARMA GMBH ES DE/H/1250/01/DC 34009 577 863 2 8 ASTELLAS PHARMA GMBH FR DE/H/1250/01/DC 34009 577 864 9 6 ASTELLAS PHARMA GMBH FR DE/H/1250/01/DC 1665/11010151 ASTELLAS PHARMA GMBH LU DE/H/1250/01/DC 1665/11010151 ASTELLAS PHARMA GMBH LU DE/H/1250/01/DC 44/499/11-C ASTELLAS PHARMA GMBH CZ EMA/699929/2017 Page 4/6

Levact 2,5 mg/ml, prášek pro přípravu koncentrátu pro přípravu infuzního roztoku Levact 2.5 mg/ml powder for concentrate for solution for infusion Levact 2.5 mg/ml powder for concentrate for solution for infusion Levact 25mg Powder for Concentrate for Solution for Infusion Levact, 2,5 mg/ml, proszek do sporzadzania koncentratu roztworu do infuzji Levact, 2,5 mg/ml, proszek do sporzadzania koncentratu roztworu do infuzji Levact, pulver til koncentrat til infusionsvæske, opløsning Levact, pulver til koncentrat til infusionsvæske, opløsning Leνact 2,5 mg/ml κόνις για πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση Leνact 2,5 mg/ml κόνις για πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση DE/H/1250/01/DC 44/499/11-C ASTELLAS PHARMA GMBH CZ DE/H/1250/001 PL 14427/0026 ASTELLAS PHARMA GMBH UK DE/H/1250/001 PL 14427/0026 ASTELLAS PHARMA GMBH UK DE/H/1250/001 PA 731/5/1 ASTELLAS PHARMA GMBH IE DE/H/1250/01/DC 17316 ASTELLAS PHARMA GMBH PL DE/H/1250/01/DC 17316 ASTELLAS PHARMA GMBH PL DE/H/1250/001 42091 ASTELLAS PHARMA GMBH DK DE/H/1250/001 42091 ASTELLAS PHARMA GMBH DK DE/H/1250/01/DC 20999 ASTELLAS PHARMA GMBH CY DE/H/1250/01/DC 20999 ASTELLAS PHARMA GMBH CY DE/H/1250/001 3838/2011/04 ASTELLAS PHARMA GMBH RO DE/H/1250/001 3838/2011/01 ASTELLAS PHARMA GMBH RO EMA/699929/2017 Page 5/6

Ribovact 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning Ribovact 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning Левакт 2,5 mg/ml прах за концентрат за инфузионен разтвор Левакт 2,5 mg/ml прах за концентрат за инфузионен разтвор DE/H/1250/001 3838/2011/03 ASTELLAS PHARMA GMBH RO DE/H/1250/001 3838/2011/02 ASTELLAS PHARMA GMBH RO DE/H/1250/01/DC 3838/2011/03 ASTELLAS PHARMA GMBH RO DE/H/1250/01/DC 45893 ASTELLAS PHARMA GMBH SE DE/H/1250/01/DC 45893 ASTELLAS PHARMA GMBH SE DE/H/1250/01/DC 20110498 ASTELLAS PHARMA GMBH BG DE/H/1250/01/DC 20110498 ASTELLAS PHARMA GMBH BG EMA/699929/2017 Page 6/6